Picotamide

Names

[ Name ]:
Picotamide

[Synonym ]:
EINECS 251-245-7
MFCD00866792
4-methoxy-N,N'-bis-pyridin-3-ylmethyl-isophthalamide
Plactidil
picotamide
4-Methoxy-N,N'-bis(3-pyridinylmethyl)-1,3-benzenedicarboxamide
G 137

Biological Activity

[Description]:

Picotamide is a combined inhibitor of thromboxane A2 (TxA2) synthase and receptor. Picotamide has antiplatelet activity. Picotamide promotes the reduction of microalbuminuria and the inhibition of growth of carotid plaques in diabetes. Picotamide can be used for researching acute or chronic cardiovascular diseases[1].

[Related Catalog]:

Research Areas >> Cardiovascular Disease

Signaling Pathways >> GPCR/G Protein >> Prostaglandin Receptor

[References]

[1]. Celestini A, et al. A review of picotamide in the reduction of cardiovascular events in diabetic patients. Vasc Health Risk Manag. 2007;3(1):93-98.

Chemical & Physical Properties

[ Density]:
1.246g/cm3

[ Boiling Point ]:
668.1ºC at 760mmHg

[ Melting Point ]:
124ºC

[ Molecular Formula ]:
C₂₁H₂₀N₄O₃

[ Molecular Weight ]:
376.40900

[ Flash Point ]:
357.8ºC

[ Exact Mass ]:
376.15400

[ PSA ]:
93.21000

[ LogP ]:
3.12700

[ Index of Refraction ]:
1.614

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: CZ2235500

CHEMICAL NAME :: 1,3-Benzenedicarboxamide, N,N'-bis(3-pyridinylmethyl)-4-methoxy-

CAS REGISTRY NUMBER :: 32828-81-2

BEILSTEIN REFERENCE NO. :: 0499268

LAST UPDATED :: 199612

DATA ITEMS CITED :: 3

MOLECULAR FORMULA :: C21-H20-N4-O3

MOLECULAR WEIGHT :: 376.45

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: BAXXDU British UK Patent Application. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Volume(issue)/page/year: #2080288

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1205 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: USXXAM United States Patent Document. (U.S. Patent Office, Box 9, Washington, DC 20231) Volume(issue)/page/year: #3973026

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Mammal - dog

DOSE/DURATION :: 3 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: BAXXDU British UK Patent Application. (U.S. Patent and Trademark Office, Foreign Patents, Washington, DC 20231) Volume(issue)/page/year: #2080288

Safety Information

[ Personal Protective Equipment ]:
Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter

[ RIDADR ]:
NONH for all modes of transport

[ RTECS ]:
CZ2235500

[ HS Code ]:
2933399090

Customs

[ HS Code ]: 2933399090

[ Summary ]:
2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Articles

Antivasoconstrictor and antiaggregatory activities of picotamide unrelated to thromboxane A2 antagonism.

Thromb. Haemost. 78(5) , 1385-91, (1997)

Picotamide is a dual thromboxane (Tx) A2 receptor antagonist/Tx synthase inhibitor although some observations suggest an anti-vasoconstrictor effect independent of TxA2 inhibition/antagonism. The aim ...

Determinants of fibrinogen in an Italian population suffering from claudication. Lower fibrinogen in the south compared to middle and north of Italy. The ADEP Group.

Haematologica 83(8) , 701-7, (1998)

Prospective studies have shown that high plasma levels of fibrinogen are independently associated with the risk of cardiovascular complications. In patients suffering from peripheral vascular disease ...

Thromboxane inhibition improves renal perfusion and excretory function in severe congestive heart failure.

J. Am. Coll. Cardiol. 42(1) , 133-9, (2003)

The aim of this study was to evaluate whether thromboxane inhibition can favorably affect renal perfusion and clinical conditions in patients affected by severe heart failure.The renal formation of th...